1,446,611 Shares in Pulse Biosciences, Inc $PLSE Purchased by Bank of America Corp DE

Bank of America Corp DE acquired a new position in Pulse Biosciences, Inc (NASDAQ:PLSE - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,446,611 shares of the company's stock, valued at approximately $40,115,000. Bank of America Corp DE owned approximately 2.09% of Pulse Biosciences as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of PLSE. Deutsche Bank AG bought a new position in shares of Pulse Biosciences during the second quarter valued at approximately $687,000. Legal & General Group Plc bought a new position in Pulse Biosciences in the second quarter worth approximately $395,000. BlackRock Inc. bought a new position in Pulse Biosciences in the second quarter worth approximately $40,672,000. Cetera Investment Advisers purchased a new stake in Pulse Biosciences during the first quarter worth $387,000. Finally, Bank of New York Mellon Corp purchased a new stake in Pulse Biosciences during the second quarter worth $1,196,000. 76.95% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Pulse Biosciences

In other Pulse Biosciences news, COO Liane Teplitsky bought 1,001 shares of the firm's stock in a transaction on Tuesday, September 1st. The shares were acquired at an average cost of $49.95 per share, with a total value of $49,999.95. Following the purchase, the chief operating officer directly owned 4,095 shares of the company's stock, valued at $204,545.25. This trade represents a 32.35% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders purchased 4,095 shares of company stock worth $199,931 in the last three months. 74.00% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several brokerages have issued reports on PLSE. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Pulse Biosciences in a research report on Friday, July 17th. Canaccord Genuity Group upped their price objective on Pulse Biosciences from $32.00 to $43.00 and gave the stock a "buy" rating in a research note on Monday, August 10th. Wall Street Zen raised Pulse Biosciences from a "sell" rating to a "hold" rating in a research report on Sunday, September 6th. Freedom Capital upgraded Pulse Biosciences to a "strong-buy" rating in a research note on Wednesday, September 9th. Finally, Needham & Company LLC initiated coverage on shares of Pulse Biosciences in a report on Monday, August 17th. They issued a "buy" rating and a $58.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $45.25.

Pulse Biosciences Price Performance

Shares of PLSE opened at $53.31 on Tuesday. The company's fifty day moving average price is $43.39 and its 200-day moving average price is $30.51. Pulse Biosciences, Inc has a 1-year low of $12.56 and a 1-year high of $58.90. The firm has a market capitalization of $3.77 billion, a PE ratio of -45.18 and a beta of 1.63.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.07). The company had revenue of $0.43 million during the quarter, compared to analysts' expectations of $0.53 million. Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%. As a group, research analysts anticipate that Pulse Biosciences, Inc will post -1.29 EPS for the current fiscal year.

About Pulse Biosciences

Pulse Biosciences, Inc is a medical technology company developing proprietary bioelectric therapies based on its Nano-Pulse Stimulation technology. The platform delivers ultrashort electrical pulses designed to affect targeted cells while limiting thermal damage to surrounding noncellular tissue.

The company's primary product is the CellFX System, which is designed to deliver Nano-Pulse Stimulation treatments for certain dermatological conditions. Pulse Biosciences is also developing additional applications for its technology in areas including cardiac procedures and other medical specialties.

Pulse Biosciences was founded in 2014 and is headquartered in Hayward, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.